Lasa Supergenerics Ltd - 540702 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on February 04, 2022 for Omkar Pravin Herlekar Lasa Supergenerics Ltd - 540702 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Omkar Pravin Herlekar Lasa Supergenerics Ltd - 540702 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for BNP Enterprises Lasa Supergenerics Ltd - 540702 - Board Meeting Intimation for To Consider, Approve And Take On Record Of Un-Audited Financial Results Along With Limited Review Report For The Quarter Ended December 31, 2021
Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2022 ,inter alia, to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of the India (Listing Obligation and Disclosure Requirement) Regulation, 2015 notice is hereby given that Meeting of The Board of Director of the Company is scheduled to be held on Monday, February 07, 2022 to consider, approve and take on record of Un-audited financial results along with limited review report for the quarter ended December 31, 2021 and / or to discuss and any other business / matter with the permission of chair. Lasa Supergenerics Ltd - 540702 - Shareholding for the Period Ended December 31, 2021
Lasa Supergenerics Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here Lasa Supergenerics Ltd - 540702 - Intimation Of Filing Of An Application Before The National Company Law Tribunal Under Section 7 Of Insolvency And Bankruptcy Code, 2016 ('IBC')
We wish to inform you that a petition is being filed under Section 7 of Insolvency and Bankruptcy Code, 2016 by Bank of Baroda, alleged Financial Creditor of the Company through Mrs. Rathina Maravarman, Advocate for Financial Creditor before the National Company Law Tribunal- Mumbai Branch alleging default in payment amounting to Rs. 26,79,46,546.25 (Twenty Six crore Seventy nine lakhs forty six thousand five hundred and forty six rupees and twenty five paisa) (Including alleged interest and penalties) and seeking initiation of Corporate Insolvency Resolution Process (CIRP) against the Company Lasa Supergenerics Ltd - 540702 - Statement Of Investor Complaints For The Quarter Ended December 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Ankita ShettyDesignation :- Company Secretary and Compliance Officer Lasa Supergenerics Ltd - 540702 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2021 received from Bigshare Services Private Limited, Registrar and Share Transfer Agent of the Company. Lasa Supergenerics Ltd - 540702 - Closure of Trading Window
This is to inform you that as per the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders in terms of (Prohibition of Insider Trading) Regulations, 2015, as amended, the trading window for dealing in the equity shares of the Company has been closed for designated employees and their immediate relatives w.e.f. January 01, 2022 till 48 hours after the declaration of financial results (both days inclusive) for the quarter ended December 31, 2021. Lasa Supergenerics Ltd - 540702 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
We wish to inform you that the Company is conducting analyst meet for Pharma Sector Analyst